10x Genomics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Serge Saxonov
- Full Time Employees
- 1,178
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6230 Stoneridge Mall Road Pleasanton CA United States of America 94588-3260
- IPO Date
- Sep 12, 2019
- CIK
- 0001770787
- Website
- 10xgenomics.com
- Similar Companies
- Business
- 10x Genomics, Inc. (NASDAQ: TXG) develops and sells instruments, consumables, and software for analyzing biological systems at the single-cell and spatial level. The company offers Chromium instruments and single cell gene expression, immune profiling, ATAC-seq, and multiome analysis kits; Visium and Xenium platforms for spatial gene expression and protein analysis; and GEM-X technology for enhanced single-cell resolution; as well as bioinformatics software including Cell Ranger, Loupe Browser, and Space Ranger. Headquartered in Pleasanton, California, and founded in 2012, 10x Genomics operates globally, serving academic institutions, biotechnology firms, pharmaceutical companies, and clinical research organizations primarily in North America, Europe, and Asia. In recent developments, the company launched GEM-X in late 2023, significantly improving single-cell capture efficiency and data quality for genomic applications; expanded its Xenium in situ platform with Xenium Prime for high-throughput spatial biology workflows; and strengthened its capabilities through strategic collaborations with leading biotech firms on multi-omics research initiatives. These advancements position 10x Genomics at the forefront of the spatial genomics and single-cell sequencing segments within the life sciences tools industry.
Company News
A Look at 10x Genomics Inc (TXG) After 3.5% Decline -- GF Value $18.31 vs Price $69.86
10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
10x Genomics Announces New Collaboration to Advance Single Cell and Spatial Applications Across Solid Tumors and Blood Cancers
Torex Gold Targets Growth, C$350M Returns and Morelos Expansion
10x Genomics Begins Atera Shipments as Spatial Biology Demand Rises
10x Genomics Announces Sentira, a New Computational Platform to Turn Complex Biological Data Into Experimental Conclusions
10x Genomics Begins Global Shipments of Atera, Putting Unprecedented Spatial Biology Capabilities in Researchers' Hands
10x Genomics (NASDAQ:TXG) Stock: Insider Shehnaaz Suliman Sells 5,723 Shares
10x Genomics (NASDAQ:TXG) Stock: Insider Serge Saxonov Sells 25,000 Shares
3 Analysts, 3 Trades to Make Today
10x Genomics Inc (TXG) Shares Surge 3.3% -- What GF Score of 56 Tells Investors
Analyzing MindWalk (NASDAQ:HYFT) & 10x Genomics (NASDAQ:TXG)
HB Wealth Management LLC Invests $285,000 in 10x Genomics $TXG
Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research
10x Genomics Inc (TXG) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 56/100
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences